Clinicopathological Significance of Caveolin-1 Expression by Cancer-associated Fibroblasts in Lung Adenocarcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2016 Oct 25

PMID 27771795

Citations 14

Authors

Kei Shimizu

Keisuke Kirita

Keiju Aokage

Motohiro Kojima

Tomoyuki Hishida

Takeshi Kuwata

Satoshi Fujii

Atsushi Ochiai

Kazuhito Funai

Junji Yoshida

Masahiro Tsuboi

Genichiro Ishii

Affiliations

Soon will be listed here.

Abstract

Purpose: Caveolin is an essential constituent of caveolae and has many biological functions. Expression of caveolin-1 in cancer cells was reported to be a prognostic marker in several types of cancers, the prognostic significance of its expression in cancer-associated fibroblasts (CAFs) has not been investigated. This study aimed to evaluate the clinicopathological significance of expression by CAFs in lung adenocarcinoma.

Methods: We examined caveolin-1 expression in both CAFs and cancer cells in stage I invasive lung adenocarcinoma (n = 412) and analyzed the relationship between the expression and clinicopathological factors.

Results: Caveolin-1 expression by CAFs and cancer cells was observed in 12.1% and 7.8% of adenocarcinomas, respectively. Tumors with caveolin-1-positive CAFs had vascular and pleural invasion significantly more frequently than those with caveolin-1-negative CAF (p < 0.05). This was also the cases with tumors with caveolin-1-positive cancer cells (p < 0.01). Caveolin-1 expression by CAFs and that by cancer cells were significant predictors of shorter recurrence-free survival (p < 0.001). Caveolin-1 expression by CAFs and cancer cells was found in 25% and 30% of solid predominant subtype, respectively, but only 9.2% and 2.7% of non-solid predominant subtype, respectively. The frequency of cases with caveolin-1-positive CAFs or cancer cells was significantly higher in the solid predominant subtype than in non-solid predominant subtype (p < 0.001).

Conclusions: Our current results highlight the prognostic importance of caveolin-1 expression by CAFs in stage I lung adenocarcinoma and provide new insights into the biological significance of caveolin-1 in the tumor microenvironment, especially in microenvironment of solid predominant adenocarcinoma.

Citing Articles

Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer.

Tokhanbigli S, Haghi M, Dua K, Oliver B Cancer Drug Resist. 2024; 7:32.

PMID: 39403603 PMC: 11472577. DOI: 10.20517/cdr.2024.55.

Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression.

Gu X, Zhu Y, Su J, Wang S, Su X, Ding X Redox Biol. 2024; 74:103209.

PMID: 38861833 PMC: 11215341. DOI: 10.1016/j.redox.2024.103209.

Research trends and hotspots on the links between caveolin and cancer: bibliometric and visual analysis from 2003 to 2022.

Tan Y, Song Q Front Pharmacol. 2023; 14:1237456.

PMID: 37576808 PMC: 10416243. DOI: 10.3389/fphar.2023.1237456.

Caveolin-1 in situ expression in glomerular and peritubular capillaries as a marker of ultrastructural progression and severity of renal thrombotic microangiopathy.

Vasuri F, Lisi A, Ciavarella C, Degiovanni A, Fabbrizio B, Valente S J Nephrol. 2023; 36(8):2327-2333.

PMID: 37480399 DOI: 10.1007/s40620-023-01645-5.

Molecular and clinical characterization of PTRF in glioma via 1,022 samples.

Sun S, Yang C, Wang K, Huang R, Zhang K, Liu Y BMC Cancer. 2023; 23(1):551.

PMID: 37322408 PMC: 10273567. DOI: 10.1186/s12885-023-11001-2.

References

van den Heuvel A, Schulze A, Burgering B . Direct control of caveolin-1 expression by FOXO transcription factors. Biochem J. 2004; 385(Pt 3):795-802. PMC: 1134756. DOI: 10.1042/BJ20041449. View

Parton R, Simons K . The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007; 8(3):185-94. DOI: 10.1038/nrm2122. View

Tse E, Ko F, Tung E, Chan L, Lee T, Ngan E . Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol. 2011; 226(4):645-53. DOI: 10.1002/path.3957. View

Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S . Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem. 1998; 272(52):33416-21. DOI: 10.1074/jbc.272.52.33416. View

Simpkins S, Hanby A, Holliday D, Speirs V . Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 2012; 227(4):490-8. DOI: 10.1002/path.4034. View

Couet J, Sargiacomo M, Lisanti M . Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997; 272(48):30429-38. DOI: 10.1074/jbc.272.48.30429. View

Burgermeister E, Tencer L, Liscovitch M . Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene. 2003; 22(25):3888-900. DOI: 10.1038/sj.onc.1206625. View

Thomas C, Smart E . Caveolae structure and function. J Cell Mol Med. 2008; 12(3):796-809. PMC: 4401128. DOI: 10.1111/j.1582-4934.2008.00295.x. View

Li S, Couet J, Lisanti M . Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem. 1996; 271(46):29182-90. PMC: 6687395. DOI: 10.1074/jbc.271.46.29182. View

10.

Karam J, Lotan Y, Roehrborn C, Ashfaq R, Karakiewicz P, Shariat S . Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 2007; 67(6):614-22. DOI: 10.1002/pros.20557. View

11.

Goetz J, Minguet S, Navarro-Lerida I, Lazcano J, Samaniego R, Calvo E . Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011; 146(1):148-63. PMC: 3244213. DOI: 10.1016/j.cell.2011.05.040. View

12.

Senetta R, Trevisan E, Ruda R, Maldi E, Molinaro L, Lefranc F . Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol. 2009; 68(4):425-31. DOI: 10.1097/NEN.0b013e31819ed0b7. View

13.

Williams T, Lisanti M . The caveolin proteins. Genome Biol. 2004; 5(3):214. PMC: 395759. DOI: 10.1186/gb-2004-5-3-214. View

14.

Calon A, Tauriello D, Batlle E . TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol. 2014; 25:15-22. DOI: 10.1016/j.semcancer.2013.12.008. View

15.

Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M . Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer. 2009; 9:65. PMC: 2656543. DOI: 10.1186/1471-2407-9-65. View

16.

Yang G, Truong L, Wheeler T, Thompson T . Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999; 59(22):5719-23. View

17.

Connolly E, Freimuth J, Akhurst R . Complexities of TGF-β targeted cancer therapy. Int J Biol Sci. 2012; 8(7):964-78. PMC: 3399319. DOI: 10.7150/ijbs.4564. View

18.

Park D, Razani B, Lasorella A, Schreiber-Agus N, Pestell R, Iavarone A . Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry. 2001; 40(11):3354-62. DOI: 10.1021/bi002787b. View

19.

Senetta R, Stella G, Pozzi E, Sturli N, Massi D, Cassoni P . Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med. 2013; 17(3):325-36. PMC: 3823014. DOI: 10.1111/jcmm.12030. View

20.

Wu D, Terrian D . Regulation of caveolin-1 expression and secretion by a protein kinase cepsilon signaling pathway in human prostate cancer cells. J Biol Chem. 2002; 277(43):40449-55. DOI: 10.1074/jbc.M206270200. View